Gufic Biosciences share news, announcements and annual reports
NSE: GUFICBIOBSE: 509079Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 30 Oct 2026. Previous close ₹418.80.
30 Oct: open ₹416.90, high ₹423.00, low ₹407.70
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,147 Cr959th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 56.46
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.24
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.02%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.58
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 70,25448.5% delivered
Gufic Biosciences share news and announcements
608 announcements, routine notices left out, newest first. Page 3 of 13.
Aug 2024
14 Aug · Results
14 Aug · Board meeting
9 Aug · Analysts
6 Aug · Analysts
1 Aug · Rating
Jun 2024
28 Jun · Management
27 Jun · Disclosure
27 Jun · Board meeting
13 Jun · Analysts
11 Jun · Legal
The exchange asked on 10 Jun 2024
May 2024
31 May · Retirement
29 May · Dividend
29 May · Results
24 May · Analysts
Apr 2024
25 Apr · Board meeting
Mar 2024
15 Mar · Analysts
14 Mar · Updates
7 Mar · Analysts
Feb 2024
14 Feb · Business
14 Feb · Board meeting
14 Feb · Results
12 Feb · Analysts
Jan 2024
30 Jan · Updates
Nov 2023
18 Nov · Updates
16 Nov · Legal
The exchange asked on 16 Nov 2023
10 Nov · Analysts
9 Nov · Results
9 Nov · Board meeting
Oct 2023
11 Oct · Board meeting
Sep 2023
29 Sep · Meeting
27 Sep · Board meeting
14 Sep · Updates
11 Sep · Analysts
6 Sep · Corporate action
5 Sep · Analysts